4.3 Article

Prolonged overall survival of patients with leptomeningeal carcinomatosis from nonsmall cell lung cancer

Journal

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume 12, Issue 5, Pages 126-129

Publisher

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0973-1482.191638

Keywords

Intrathecal therapy; leptomeningeal metastasis; nimotuzumab; nonsmall cell lung cancer

Categories

Ask authors/readers for more resources

Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy. Nimotuzumab was well tolerated used in intrathecal therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available